作者:卓帝伯 来源:原创 时间:2026-08-26 阅读:361081 次

亮剑

Jobs, Inflation Data This Week as Markets Key in on September Fed Meeting_我的网站

父女七日变

一 |     一                    今天继续介绍刚在欧洲肿瘤内科学会(ESMO)年会上公布,并同步发表在《新英格兰医学杂志》上的优秀研究。    

Last week ended with Federal Reserve Chairman Jerome Powell reiterating the central bank’s commitment to keeping interest rates high enough to choke off economic activity while bringing inflation back down to its 2% annual target.
“It is the Fed's job to bring inflation down to our 2 percent goal, and we will do so,” Powell said during his speech in Jackson Hole, Wyoming, on Friday. “We have tightened policy significantly over the past year. Although inflation has moved down from its peak – a welcome development – it remains too high. We are prepared to raise rates further if appropriate, and intend to hold policy at a restrictive level until we are confident that inflation is moving sustainably down toward our objective.”
That will be done while also keeping a close eye on incoming economic data, Powell added.
Well, there will be no shortage of new data this week from a consumer confidence reading for August, an update on second quarter gross domestic product, home prices for June and pending home sale for July, along with a bevy of reports on the labor market. And no doubt the stock and bond markets will continue to analyze Powell’s comments and price in any anticipated actions by the Fed.
“We believe the Fed will remain vigilant and data dependent in determining whether rates sustained at current levels for a longer period of time or further rate rises will be needed,” Vanguard senior economist Andrew Patterson said on Friday. “Our baseline is for the latter, another 1-3 hikes are possible over the next several months and into next year before leaving them on hold for some time and only cutting when broader macro conditions weaken, resulting in a shallow recession.”
One piece of the puzzle for Powell will be the health of the labor market. On Tuesday, the Labor Department will release the number of job openings as of the end of July. Analysts are forecasting the number at 9.45 million following June’s 9.6 million.
On Wednesday, private payroll firm ADP will release its monthly employment survey for August with 194,000 jobs expected following July’s supercharged 324,000 number.
But Friday brings the big data highlight of the week with the government’s report on nonfarm payrolls for August. Economists foresee another slip to 168,000 from 187,000.
Sandwiched in between are personal income and spending numbers for July as well as that month’s personal consumption price expenditures index. The inflation measure, while not as commonly known as the consumer price index, is one closely followed by the Fed. One reason that inflation has not come down closer to the Fed’s 2% annual target is that consumers continue to spend, buoyed by wage gains.
“Recession keeps getting pushed back and the staying power of the consumer is a key reason why,” said Sam Bullard, managing director and senior economist at Wells Fargo’s corporate and investment banking group. “Even as credit becomes harder to access for consumers and pandemic era savings get closer to running out, consumers continue to spend. June marked the largest monthly gain in real consumption since January, which suggests that PCE is set to start the third quarter on solid ground.”
The Fed’s monetary policy committee will meet again on Sept. 20. Although expectations have been for no change in the level of interest rates after July’s quarter-point increase, the odds of a hike at the next scheduled meeting in November are starting to creep up.
CME Group’s futures trading price the odds of a rate hike at the Fed’s November meeting at roughly 57%, up from 36% prior to Powell’s Jackson Hole comments.
。今天这个很特别,因为论文作者全是中国人。这次研究从药物开发到临床研究,都来自中国。                             在所有泌尿系统肿瘤中,膀胱癌是最常见的一种,中国每年新发病例近10万人。膀胱癌最常出现在中老年男性身上,重要原因就是吸烟。吸烟是膀胱癌最重要的单一危险因素,吸烟者的风险是不吸烟者的3到4倍。                   膀胱癌如果发现得早,生存率挺高的,但一旦进展为晚期,情况就完全不同了。晚期膀胱癌很容易耐药和复发,是“最难啃的骨头”之一。                   过去几十年,化疗一直是这类患者的主力治疗手段,但效果有限,中位生存期只有一年多,副作用还挺大。

二 | 最近,有两类新药给患者带来了新希望,一个是免疫药物,一个是抗体偶联药物(英文缩写是ADC)。                   膀胱癌是对免疫治疗整体响应比较好的一类肿瘤,多款PD-1/PD-L1 类免疫药物都在膀胱癌中获批,包括大家熟悉的K药,O药等。                   抗体偶联药物也是最近很火的一类药物,它的本质是“导弹模式”:用靶向肿瘤的抗体来把化疗药带到肿瘤细胞附近,从而进行更精准的杀伤。

三 | 膀胱癌中最早获批的一个抗体偶联药物是维恩妥尤单抗,它的靶点是膀胱癌表面的Nectin-4蛋白。                   这两类新药都已经获批,但单独都有自己的局限,比如免疫治疗单用有效率偏低,而抗体偶联药物副作用偏大,疗效持续性不够长。于是有科学家想到,能不能强强联合,一面用导弹轰炸肿瘤,一面激活免疫,或许1+1能大于2?                    说干就干,这次的研究就是这样。科学家把两个已经在中国获批,用于膀胱癌治疗的国产新药联合了起来,一个是PD1免疫药物,特瑞普利单抗,另一个是针对HER2的抗体偶联药物,维迪西妥单抗(有人可能熟悉它以前的代号RC48)。                   有人可能会问,HER2不是乳腺癌靶点么,怎么膀胱癌也能用?                    确实,HER2最早是在乳腺癌中成功的靶点。曲妥珠单抗等HER2靶向药的出现,让无数HER2阳性乳腺癌患者获得了长期生存。但其实HER2在别的肿瘤上也有表达,包括膀胱癌。                   事实上,超过一半的膀胱癌都有HER2蛋白表达,只不过以往曲妥珠单抗在这里效果不好,所以没有作为一个靶点来看。但随着维迪西妥单抗这样新型抗体偶联药物出现,改变了这个结果。2021年,它已经在中国获批用于HER2阳性膀胱癌的二线治疗。                   这次临床研究,目标是改变一线治疗标准。研究纳入了484名HER2表达阳性的晚期尿路上皮癌患者(主要是膀胱癌),然后随机分为两组:一组接受维迪西妥单抗+特瑞普利单抗,另一组接受传统化疗。                   结果很清楚,新药各个指标都碾压化疗。                             患者客观缓解率高达76.1%,也就是说,每四个接受新方案的患者中,就有三个人肿瘤明显缩小。

四 | 中位无进展生存期从6.5个月延长到13.1个月,中位总生存期从16.9个月延长到31.5个月,都几乎翻倍了。                   生存曲线上,两条线分得越开,效果就越好。                   当然,任何疗法都有副作用。新组合疗法安全性比化疗整体好一点,但有一些特别的副作用,比如周围神经病变(手脚麻木)和间质性肺病,它们虽然发生率低,但如果严重会很危险,甚至致命,所以如果后续上市后使用,需要大家配合医生严密监控,尽量早期干预。                   二                    值得一提的是,这已经不是第一个在膀胱癌取得成功的免疫+抗体偶联药物组合了。

五 |                    在此之前,两个进口药,维恩妥尤单抗和帕博利珠单抗(K药),也是在《新英格兰医学杂志》,发表了代号为EV-302的三期随机对照研究结果,同样是完爆化疗:患者中位生存时间从16.1个月,延长到了31.5个月,几乎翻了一倍,患者死亡风险降低了53%。                             因为优异的数据,今年1月,中国药监局已经批准了这个联合疗法,用于局部晚期或转移的尿路上皮癌患者的一线治疗。                   虽然不同研究的数据不能直接比较,但整体看起来,这次国产药物组合的结果也处于同一水平上,获批应该只是时间问题。                   三                    最近几年,中国国产药物研发水平突飞猛进。虽然从0到1的原创还比较少,但整体水平已经和十年前不可同日而语。这次“纯国产”的研究能发表在最顶尖的临床医学杂志上,就体现了对我国药物研发和临床实验能力整体的高度认可。                   一旦中国人做得好,就会让这个行业变得更卷,创新药也不例外。瑞普利单抗和维迪西妥单抗作为本土开发的新药,如果获批,肯定会让膀胱癌治疗性价比变得更高,对国内患者无疑是好消息。                   膀胱癌患者一线选择已经有多个选择,包括维恩妥尤单抗+帕博利珠单抗,纳武利尤单抗+化疗,现在又加上了维迪西妥单抗+瑞普利单抗。随着新药出现,我相信以后一线纯用化疗的膀胱癌患者将会越来越少。                   至于这些组合疗法怎么选,大概率会是基于生物标记物,比如HER2、Nectin-4、PD-L1蛋白的表达。越来越多膀胱癌患者的肿瘤会被拿去检测这些蛋白的水平,然后根据这些标记物是否表达,以及表达的多少,我们可以选择成功概率最高的一个。                   当然,现在还远没有到终点,科学的脚步不会停止。还有很多研究正在进行。                   比如耐药机制和后续选择。

六 | 中位总生存超过30个月令人鼓舞,但其中多少人疗效能持续?甚至临床治愈?耐药机制如何?                    再比如,是否可以把这个组合用于更早的患者,用于手术前新辅助治疗或手术后辅助治疗?                    通过精准的靶向识别和免疫激活,新药已经给晚期膀胱癌患者点燃了新的希望。期待更多突破能够迅速进入临床实践,真正改变患者的命运。                   致敬科学,致敬生命!                    *本文旨在科普癌症新药背后的科学,不是药物宣传资料,更不是治疗方案推荐。

七 | 如需获得疾病治疗方案指导,请前往正规医院就诊。                   参考文献          1. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med 2025          2. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024; 390: 875-88.                    本文来自微信公众号:菠萝因子,作者:80后菠萝博士。

八 |

Current article:http://www.lichuorenrenyitankanmeimu.cfd/list_3aw/ra7rs.ppt

Published on:05:29:42